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ABSTRACT 
Objective: The objective of this work was to evaluate the in vitro release performance of metformin hydrochloride formulations (500-mg tablets) 
using the hydrodynamic environment of the flow-through cell method. Results were compared with those generated by the official dissolution test 
(USP basket apparatus). 
Methods: The reference drug product and three generic formulations were tested with phosphate buffer pH 6.8 as dissolution medium. Dissolution 
profiles were carried out with an automated flow-through cell apparatus using laminar flow at 16 ml/min. Drug was quantified at 233 nm during 45 
min. Dissolution profiles were compared with the calculation of f2 similarity factor, mean dissolution time, dissolution efficiency, t50% and t63.2%. 
Dissolution data were adjusted to several mathematical models such as Makoid-Banakar, Peppas-Sahlin, Weibull and Logistic. 
Results: With the flow-through cell method and at 45 min less than 60% of metformin hydrochloride dissolved was found, while with the USP 
basket apparatus, less than 75% of the drug was found. Some generic formulations showed f2>50 with both USP apparatuses, but statistical 
comparisons of parameters indicated significant differences between their dissolution profiles and reference. Due to variability obtained no 
dissolution profiles were compared by model-dependent approach. 
Conclusion: To demonstrate safe interchangeability between metformin hydrochloride generic formulations and reference bioequivalence studies 
should be performed. It is important post-marketing monitoring of the commercial formulations because health regulatory agencies of each country 
must ensure drug products with quality, safety, and efficacy at the lowest possible cost. 
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INTRODUCTION 
Generics are off-patent formulations that contain the same active 
pharmaceutical ingredient, and the same dose, as reference drug 
product [1]. During the dissolution tests, many generic formulations 
have shown significant differences from their branded counterparts. 
Metformin hydrochloride is manufactured as generic drug products 
and by the results reported by other authors there is a need to 
evaluate generics even after going on sale with the aim of offering 
the population safe and quality medicines. 
Metformin is a member of the biguanide class of drugs and is used in 
the treatment of type 2 diabetes mellitus [2]. This type of diabetes is 
characterized by abnormally high levels of glucose in the blood due to 
either insulin resistance of the cells or too much glucose production in 
the liver or a combination of both situations [3]. Metformin 
hydrochloride is a white to off-white crystalline compound and it is 
absorbed predominately from the small intestine [4]. Molecular 
structure of metformin hydrochloride is shown in fig. 1. 
 
 
Fig. 1: Molecular structure of metformin hydrochloride 
 
Metformin is a class III drug (high solubility/low permeability) [5] 
so the limiting step for its absorption is the passage through the 
biological membranes. For class III drugs, a biowaiver can be 
considered following certain criteria, one of them, more than 85% of 
the drug must be dissolved in at least 15 min in standard dissolution 
media at pH 1.2, 4.5, and 6.8 [6]. On the other hand, the USP 
dissolution test designed to verify the quality of metformin 
hydrochloride tablets point to the use of USP basket apparatus at 
100 rpm with 1000 ml of phosphate buffer pH 6.8 as dissolution 
medium. Under these conditions, not less than 70% must be 
dissolved at 45 min (Q = 70%) [7]. 
About in vitro dissolution studies of metformin hydrochloride 
commercial formulations, several authors have reported limited 
works with the USP basket apparatus [8, 9]. Other manuscripts 
describe the use of USP paddle apparatus [10-16] and only one has 
reported data with the flow-through cell method [13]. Most of them 
agree with the use of phosphate buffer pH 6.8 as dissolution 
medium, while others have tested metformin hydrochloride tablets 
with simulated intestinal fluid pH 6.8 [10] and dissolution media 
within physiological pH range (pH 1.2 ‒ 6.8) [11, 12]. These results 
reflect a high variability in the dissolution performance of studied 
formulations as well as the need to develop a common dissolution 
test that allows the quality of the tablets to be properly evaluated. 
Several reports have found significant in vitro/in vivo correlation 
with data generated with the flow-through cell method [17, 18] so it 
is convenient to use this apparatus to evaluate the applicability of 
working with high solubility drugs as metformin hydrochloride 
tablets. The aim of this work is to document the in vitro release 
performance of metformin hydrochloride commercial formulations 
under the hydrodynamics of the flow-through cell method. Results 
could be of interest to manufacture better metformin hydrochloride 
formulations or to improve the in vitro evaluation schemes. 
MATERIALS AND METHODS 
Formulations and chemicals 
Metformin hydrochloride tablets (500-mg) of the reference drug product 
Dabex® (Merck S. A. de C. V. Mexico City, Mexico) and three generic 
formulations (coded as A, B, and C products) were used in the study. 
Mexican Health authorities have established Dabex® brand as a 
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reference drug product for dissolution and bioequivalence studies [19]. 
Potassium dihydrogen phosphate and sodium hydroxide were supplied 
by J. T. Baker-Mexico (Xalostoc, Mexico). Metformin hydrochloride 
standard was purchased from Sigma-Aldrich Co. (St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests were performed according to the 
procedures described in the USP [7]. 
Analytical method validation 
Dissolution method was validated according to ICH guidelines [20]. 
Method linearity, accuracy, precision, and stability were evaluated. 
Linearity 
Three standard calibration curves of metformin hydrochloride were 
prepared in the dissolution medium. Potassium dihydrogen phosphate 
buffer (0.68% w/v) adjusted with 1 M sodium hydroxide to pH 6.8 was 
used as a dissolution medium. Drug concentrations of 1.5 to 15 µg/ml 
were prepared. Absorbance measured at 233 nm with 1-cm quartz 
cells was recorded. Absorbance vs. drug concentration data was fitted 
by linear regression analysis and the coefficients of regression and 
regression analysis of variance (ANOVA) were calculated. Absorbance 
vs. metformin hydrochloride concentration proportionality was 
demonstrated by calculating the percent of relative standard deviation 
(RSD): [((standard deviation)/mean value) × 100] of the response 
factor across the calibration curve range. 
Accuracy and precision 
To validate these parameters, the standard addition method was used, 
so that matrix effects can be easily removed. Twenty tablets were 
accurately weighed and crushed in a mortar; then, quantities of 
powder of metformin hydrochloride tablets plus a quantity of 
metformin hydrochloride standard (10 mg) to finally give the 
equivalent of 80, 100, and 120% of the dose were dissolved in 1000 ml 
of phosphate buffer pH 6.8 at 37.0±0.5 °C. The USP basket apparatus at 
100 rpm was used. At 45 min the amount of metformin hydrochloride 
dissolved in each vessel was calculated with reference to a standard 
calibration curve prepared on the day of the experiment. Each 
determination was performed in triplicate. The percent of relative 
error (RE): [((found–added)/added) × 100] was taken as a measure of 
the accuracy and the RSD as a measure of precision. Determinations 
were carried out in three consecutive days. 
Stability 
Drug stability was evaluated by analyzing two solutions of metformin 
hydrochloride prepared in phosphate buffer pH 6.8 (2 and 13 µg/ml). 
These solutions were analyzed at 0 h at 25 °C and at 24 and 48 h after 
stored at 4 and 25 °C. At 24 and 48 h (at each temperature) the percent 
of absolute difference (AD): [((initial–final)/initial) × 100] recovered 
of metformin hydrochloride was calculated. 
USP basket apparatus 
Dissolution profiles of metformin hydrochloride were obtained 
using the dissolution test described in the USP [7]. USP basket 
apparatus (Model AT-7 Smart, Sotax, Basel, Switzerland) at 100 rpm 
was used (Q = 70% at 45 min). The UV/Vis spectrophotometer 
(Model Lambda 35, Perkin Elmer, USA) with 1-mm flow cells was 
used. Equipment was controlled by specific software designed by 
Sotax. Metformin hydrochloride tablets were sprinkled on 1000 ml 
of deaerated phosphate buffer pH 6.8 at 37.0±0.5 °C. Automatic 
samples were taken every 5 min to 45 min (n = 12). Metformin 
hydrochloride dissolved was determined with a standard calibration 
curve. 
Flow-through cell method 
Dissolution profiles of metformin hydrochloride were obtained with a 
flow-through cell apparatus (Model CE6, Sotax AG, Basel, Switzerland) 
and 22.6 mm cells (i.d.). Laminar flow (originated with 6 g of glass beads) 
at 16 ml/min was tested. Deaerated phosphate buffer pH 6.8 at 37.0±0.5 
°C was used as a dissolution medium. Automatic samples were taken 
every 5 min up to 45 min (n = 12). Metformin hydrochloride dissolved 
was determined in an UV/Vis spectrophotometer (Model Lambda 10, 
Perkin Elmer, USA) with 1-mm cells at 233 nm. For every trial, a 
standard calibration curve was prepared. 
Data analysis 
Dissolution profiles of reference and generic formulations were 
compared by model-independent and-dependent methods [21]. For 
model-independent comparisons, mean dissolution time (MDT) and 
dissolution efficiency (DE) were calculated. MDT is the time to 
dissolve 63.2% of drugs and it was calculated according to statistical 
moment’s theory [22, 23]. Other authors have given the MDT a value 
of 62–64% [24]. DE is the area under the dissolution curve up to a 
certain time, t, expressed as a percent of the area of the rectangle 
described by 100% dissolution at the same time [25]. Both 
parameters were calculated with the Excel add-in DDSolver program 
[26]. For model-dependent comparisons, dissolution data were 
adjusted to the hyperbola equation and with a and b values, t50%, and 
t63.2% parameters were calculated. This fit was carried out with 
SigmaPlot software (version 11.0). Generics vs. reference data 
comparisons were carried out with a one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test. 
Additionally, and for a complete analysis of dissolution profiles by 
model-dependent approach, dissolution data were fitted to Makoid-
Banakar, Peppas-Sahlin, Weibull, and Logistic equation. The model 
with the highest adjusted determination coefficient (R2adjusted) and 
the lowest Akaike Information Criterion (AIC) was chosen as the 
best-fit model [21]. Data analysis was carried out using the Excel 
add-in DD Solver program [26]. The mathematical equations of each 
model are given in table 1. 
RESULTS AND DISCUSSION 
Content uniformity and assay 
Results of content uniformity and assay tests made to metformin 
hydrochloride formulations are shown in table 2. All commercial 
formulations met the content uniformity and assay standard criteria. 
The percentages of metformin hydrochloride content ranged from 
85 to 115% and the assay test was between 90 to 110%. 
Linearity 
Mean regression equation from three standard calibration curves 
was y = 0.0836x+0.0073. linear regression was significant (R2= 
0.999, *P<0.05). The RSD value of the response factor was 2.5%. 
Accuracy and precision 
To evaluate the accuracy and precision of the dissolution method, 
analysis of several percentages of dose (80, 100, and 120%) was 
carried out for three different days (n = 3/d). The within-run and 
between-run precision and accuracy were calculated. Results are 
shown in table 3. RSD obtained was in the range of 0.24 ‒ 1.45% and 
RE was lower than 0.72% what indicates good accuracy and 
precision of the dissolution method. 
 






Makoid-Banakar 𝐹 = 𝑘𝑀𝐵 ∙ 𝑡𝑛 ∙ 𝑒−𝑘∙𝑡 
Peppas-Sahlin 𝐹 = 𝑘1 ∙ 𝑡𝑚 + 𝑘2 ∙ 𝑡2𝑚 
Weibull 





𝐹 = 100 ∙
𝑒𝛼+𝛽∙log (𝑡)
1 + 𝑒𝛼+𝛽∙log (𝑡)
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Table 2: Content uniformity and assay results of metformin hydrochloride formulations 
Key Content uniformity (%min-%max)a Assay (%)b 
R 95.13–106.07 99.76 
A 96.09–103.99 104.85 
B 100.09–115.00 98.29 
C 96.16–104.53 104.03 
an = 10, bn = 3 
 
Table 3: Accuracy and precision of the dissolution method used to determine metformin hydrochloride in commercial formulations 
 Within-daya Between-dayb 
Added (mg) Found (mg) RSD (%) RE (%) Found (mg) RSD (%) RE (%) 
400.30 397.13±0.59 0.15 -0.79 400.98±4.10 1.02 0.19 
500.64 500.38±1.18 0.24 0.15 503.01±3.27 0.65 0.54 
600.13 601.27±7.19 1.20 0.19 604.47±8.75 1.45 0.71 
Mean value±SD, an = 3, bn = 9. SD: Standard deviation 
 
Stability 
Stability of metformin hydrochloride in phosphate buffer pH 6.8 was 
evaluated, analyzing drug solutions of 2 and 13 µg/ml at different 
times and temperatures. Results are given in table 4. Results suggest 
good stability of metformin hydrochloride at both temperatures but 
only by 24 h. Validation of the dissolution method met the standard 
criteria, which generates confidence in the results obtained. 
 
Table 4: Absolute difference values of drug solutions to test drug stability 
Conc. (µg/ml) 4 °C 25 °C 
24 h 48 h 24 h 48 h 
2 -11.84 -248.85 -9.13 -256.37 
13 -0.89 -46.22 -1.11 -44.25 
Mean value, n = 8 
 
 
Fig. 2: Dissolution profiles of metformin hydrochloride reference (R) and generic formulations (A-C). The dashed line shows Q = 70%. For 
better clarity, error bars have been omitted, mean value, n = 12 
 
Dissolution studies 
Dissolution profiles of all metformin hydrochloride formulations, 
obtained with USP basket apparatus and flow-through cell method, 
are shown in fig. 2. 
Under official conditions, all drug products met the pharmacopeial Q 
criteria (Q = 70% at 45 min). Metformin hydrochloride dissolved at 
45 min are shown in table 5. Compliance with the above 
pharmacopeial tests ensures the quality of formulations. However, if 
the generic drug products are intended to be interchangeable with 
reference, none reaches>85% dissolved at 15 min so that the own 
biowaiver criteria for class III drugs cannot be applied. For 
immediate-release products manufactured with class III drugs, the 
assumption is that if their dissolution is very rapid under all 
physiological pH conditions, they can be expected to behave like oral 
solutions in vivo, since the rate-limiting step in the absorption 
process is permeability [11]. Data of drug dissolved at 15 min from 
the studied formulations are shown in table 5. Despite not having 
information on the dissolution performance of these drug products 
at pH 1.2 and 4.5 the biowaiver criteria must be met at every pH [6]. 
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Table 5: Model-independent and-dependent parameters calculated to compare dissolution profiles of generic formulations (A-C) and 
reference drug product (R) 
Key Diss at 15 min (%) Diss at 45 min (%) MDT (min) DE (%) t50% (min) t63.2% (min) 
 USP basket apparatus 
R 50.52±0.73 74.73±0.38 11.48±0.23 55.67±0.51 14.18±0.37 23.37±0.54 
A 56.81±0.86 72.96±0.45* 9.96±0.19* 56.81±0.50 13.01±0.33 21.97±0.51 
B 47.81±1.13 72.97±0.54* 13.02±0.32* 51.88±0.80* 16.83±0.61* 27.52±0.95* 
C 74.51±0.57 74.74±0.51 5.55±0.13* 65.49±0.53* 6.04±0.26* 11.90±0.47* 
 Flow-through cell method 
R 16.27±0.10 48.51±0.36 21.98±0.05 24.81±0.17 45.57±0.33 58.07±0.49 
A 22.36±0.17 56.56±1.42* 18.43±0.39* 33.26±0.40* 34.97±0.78* 48.01±1.91* 
B 16.44±0.10 46.09±0.75 21.24±0.20 24.30±0.26 48.38±0.97* 63.77±1.73* 
C 15.84±0.31 18.64±0.67* 9.61±0.24* 14.62±0.44* † † 
Mean value±SEM, n = 12. *P<0.05, SEM: Standard error medium, †Due to limited drug dissolved no data was calculated 
 
As can be seen in fig. 2, with the flow-through cell method, the rate 
and extent of metformin hydrochloride dissolved was less than the 
behavior obtained with the USP basket apparatus. Under the used 
flow-through cell conditions, no formulation showed>70% at 45 
min. Usually, with the flow-through cell method, it is possible to 
obtain slower dissolution rates than those reported with the USP 
basket or paddle apparatuses [27, 28]. This performance can be 
explained by the hydrodynamic environment of the flow-through 
cell method which better reflects the natural setting of the 
gastrointestinal tract than other USP dissolution apparatuses [29]. 
Cell size, glass beads and flow rate are critical factors to form a 
special dissolution pattern useful to compare the in vitro release 
performance of drug products. Results agree with those reported by 
Hashem et al., [13] where after working with four commercial 
products (850 and 1000-mg), phosphate buffer pH 6.8 and the USP 
paddle apparatus (100 rpm) and flow-through cell method (laminar 
flow at 8 ml/min) a slower dissolution rate was found with the flow-
through cell. On the other hand, the absolute bioavailability of 
metformin when given orally is 50 ‒ 60% [16]. This value can be 
explained, among other factors, by the low dissolution found with 
the flow-through cell method. 
If more than 85% of the drug is dissolved within 15 min, the 
dissolution profiles are considered similar without further 
mathematical calculation [12]. As no metformin hydrochloride 
formulation achieved this value, dissolution profiles were compared. 
To compare dissolution profiles between generic formulations and 
reference f1 difference and f2 similarity factors were calculated 
according to equations reported by Moore and Flanner [30]. Only f2 
similarity factor is considered an official parameter to compare 
dissolution profiles [6]. Results are given in table 6. 
 
Table 6: f1 and f2 factors calculated to compare dissolution profiles 
Key USP basket apparatus Flow-through cell method 
 f1 f2 f1 f2 
A 5.66 69.60 32.35 51.17 
B 6.51 70.01 2.68 91.86 
C 16.42 43.56 † † 
†Due to limited drug dissolved no data was calculated. 
 
Considering the accepted range to similar dissolution profiles (f1 = 0 
‒ 15 and f2 = 50 ‒ 100), only generic drug products A and B showed 
similar dissolution profiles when the USP basket apparatus was 
used. Same results were obtained with the flow-through cell method 
but due variation out of official criteria (RSD should not be more 
than 20 percent at the earlier time points and should not be more 
than 10 percent at other time points) [6], for generic product C, no 
value of f1 and f2 were calculated. This drug product has a totally 
different dissolution performance in both apparatuses; apparently, 
its formulation (excipients and/or manufacture process) showed 
high sensitivity to hydrodynamic environments of the USP basket 
apparatus and flow-through cell method. 
MDT and DE parameters as well as the percent of drug dissolved at 
45 min were used to compare dissolution profiles by a model-
independent approach. Results are shown in table 5. As can be seen 
in table 5, all generic formulations showed different dissolution 
profiles with the reference when USP basket apparatus was used 
(*P<0.05). With the flow-through cell method, only generic 
formulations A and C showed different dissolution profiles. 
Conversely, the three calculated parameters of generic product B 
support the result of similarity with reference. Our results agree 
with the results described by several authors. Villarroel Stuart et al., 
[10] reported MDT values of 5.2 to 15.3 min. Data were obtained 
with the study of seven commercial formulations (500-mg) with USP 
paddle apparatus at 75 rpm and 900 ml of simulated intestinal fluid 
pH 6.8 as dissolution medium. Hashem et al., [13] found DE values of 
54.65 to 58.85%. They worked with two references (850-mg) and 
two generic products (1000-mg) using the USP paddle apparatus at 
100 rpm and 900 ml of phosphate buffer pH 6.8. Additionally, the 
same authors reported the use of the flow-through cell method. DE 
values that they found were 44.0 to 57.86%. Results may differ from 
ours because they used 850 and 1000-mg tablets, the flow rate of 8 
ml/min, and 60 min of sampling time. 
Model-dependent parameters t50% and t63.2% were also used to 
compare dissolution profiles. Results are shown in table 5. With this 
approach, generic formulations B and C were different to reference 
when the USP basket apparatus was used (*P<0.05). With the flow-
through cell method, no formulation was similar to reference 
(*P<0.05). Our results coincide with those reported by other 
authors. Kassahun et al., [14] found t50% values between 9.39 ‒ 18.88 
min. Data were obtained with the use of six commercial formulations 
(500-mg), USP paddle apparatus at 50 rpm and 900 ml of phosphate 
buffer pH 6.8. Authors claim that t50% and t90% are dissolution 
parameters that can be used to compare dissolution profiles of 
different brands of metformin hydrochloride tablets. In our study, it 
is difficult to establish similar dissolution profiles between generic 
formulations and reference because model-independent and model-
dependent approaches, or MDT, DE, t50%, and t63.2% comparisons, do 
not match. 
In order to evaluate the influence of the hydrodynamic environment 
of the flow-through cell method and USP basket apparatus on the in 
vitro release performance of metformin hydrochloride commercial 
tablets, the results obtained were analyzed in two different ways. 
The first one with the association of t63.2% values in function of MDT 
values and the second one with the association of t50% values in 
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function of DE values. The first association allows visualizing the 
accuracy in calculating the t63.2% value (time at which each 
formulation releases 63.2% of the drug) with its equivalent 
parameter MDT. The second association allows evaluating the 
relationship between two different approaches or comparison 
methods (model-dependent vs. model-independent). Plots for the 
first association are shown in fig. 3, while for the second association, 
only the regression equations are indicated. The regression equation 
for t50% vs. DE data obtained with the USP basket apparatus was y =-
0.7998x+58.473, R2= 0.9987, with significant regression (*P<0.05). 
The regression equation for data obtained with the flow-through cell 
method was y =-1.3897x+81.13, R2= 0.9779. For both ways of 
comparison, only the best results were obtained with data generated 
by the USP basket apparatus. 
 
 
Fig. 3: Model-dependent parameter t63.2% in the function of model-independent parameter MDT calculated with metformin hydrochloride 
formulations (R, A, B, C) obtained with both dissolution equipments. Mean value, n = 12 
 
To complete comparisons by model-dependent analysis, 
metformin hydrochloride data were adjusted to several 
mathematical models commonly used to fit dissolution data. 
Results are shown in table 7. 
 
Table 7: Criteria used to choose the best fit-model 











R 0.9960 0.9975 0.9912 0.9831 0.9495 0.9036 0.9997 0.9998 
A 0.9885 0.9689 0.9966 0.9924 0.9958 0.9730 0.9948 0.9809 
B 0.9978 0.9950 0.9986 0.9890 0.9994 0.9979 0.9994 0.9982 
C 0.8294 0.7909 0.9980 0.6736 0.9495 0.9036 0.9984 0.7250 
 AIC 
R 23.43 19.17 31.33 36.61 24.99 31.08 -0.78 -4.67 
A 34.46 43.83 23.32 51.58 26.22 42.40 28.20 37.00 
B 17.13 22.94 13.51 30.97 0.14 11.72 1.00 9.79 
C 52.56 54.44 9.58 57.83 24.99 31.08 -8.96 40.03 
Mean value, n = 12 
 
According to established criteria to choose the best fit-model (higher 
value of R2 adjusted and lower value of AIC), several mathematical 
models adjusted to all formulations when the flow-through cell 
method was used. Logistic model was the best mathematical 
expression to explain dissolution data of reference, Makoid-Banakar 
to adjust generic drug products A and B and Weibull function to 
explain data of generic product C. On the other hand, when the USP 
basket apparatus was used, Peppas-Sahlin was the best fit-model to 
describe dissolution data of reference drug product and Weibull 
function to describe data of all generic formulations. Due to 
variability obtained in the adjustment of metformin hydrochloride 
dissolution data of all formulations using both USP apparatuses, no 
dissolution profiles were compared by this model-dependent 
approach. However, it is important pointing that a great variability is 
observed in the adjustment of the data with the flow-through cell 
method as metformin hydrochloride dissolution data fitted three out 
of four models used. 
The European Medicines Agency (EMA) and Food and Drug 
Administration (FDA) have pointed the criteria for the BCS-based 
biowaiver for class III drugs: high solubility and limited absorption 
for drug substance, very rapid in vitro dissolution rate for test and 
reference drug products, and no change in excipients that might 
affect bioavailability [6]. By its molecular characteristics, metformin 
is a class III drug. Membrane permeability is the rate-limiting step 
for its oral absorption. According to the WHO biowaiver testing 
procedure for class III drugs, a biowaiver can be considered if the 
multisource and comparator product are very rapidly dissolving (no 
less than 85% in 15 min at pH 1.2, 4.5, and 6.8) [31]. 
Different authors have provided the following information about 
metformin hydrochloride dissolution from commercial formulations. 
Akdag et al., [12] worked with seven metformin hydrochloride 
formulations (1000-mg) using USP paddle apparatus at 50 rpm with 
media within the physiological pH range. Only one drug product 
fulfilled the criteria of BCS-based biowaiver. Oyetunde et al., [11] 
reported a study with four formulations (500-mg) under the same 
conditions of Akdag et al., [12]. Test and comparator samples were 
not very rapidly dissolving. Our in vitro release study covered only 
phosphate buffer pH 6.8 with USP basket apparatus at 100 rpm (USP 
conditions). Same conditions were used by Olusola et al., [9] with 
eight formulations (500-mg) and found that three products 
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had>85% dissolved at 30 min and four products showed f2>50. 
Criteria of rapidly dissolution has been previously established as 
more than 85% of drug dissolved at 30 min, respectively [6]. 
Meanwhile, Adegbola et al., [8] studied 14 products (500-mg) and 
only three formulations showed>85% of drug dissolved at 15 min. 
Several authors have used phosphate buffer pH 6.8 as dissolution 
medium to test the in vitro release performance of metformin 
hydrochloride commercial formulations with the use of USP paddle 
apparatus. Kassahum et al., [14] used different drug products and only 
two of them showed>85% dissolved at 30 min. Prithi et al., [15] used 
three formulations (500-mg) and 100 rpm as an agitation rate. All 
tablets comply the Q specification (>80% dissolved at 60 min). Zakeri-
Milani et al., [16] tested six (500-mg) and two (1000-mg) products at 
100 rpm as the agitation rate. Seven formulations achieved>80% of 
drug dissolved at 30 min. Additionally, five formulations showed f2>50 
when were compared to the reference (500-mg) but data were 
calculated with six replicates of each formulation. Similar results were 
obtained by Hashem et al., [13] that worked with four drug products 
and two generics achieved f2>50 also with six replicates by drug 
product. One condition to calculate f2 similarity factor is the number of 
dosage units, it must be calculated with an average of 12 units [6]. 
Villarroel Stuart et al., [10] studied seven drug products and only one 
formulation showed<85% of drug dissolved at 15 min and the same 
product had f2<50. 
The use of the flow-through cell method to study metformin 
hydrochloride commercial formulations was only reported by 
Hashem et al., [13]; the dissolution equipment was used with 
laminar flow, cells of 22.6 mm and phosphate buffer pH 6.8 as 
dissolution medium. Two generic formulations (1000-mg) showed 
f2>50 but the reference was a drug product with a different dose 
(850-mg) and data were calculated with only six dosage units per 
drug product. 
Similarity of dissolution profiles by comparison of model-dependent 
or model-independent parameters is not accurate since the results 
do not match. For this reason, it cannot be definitively concluded 
with this form of comparison. However, by relating parameters 
obtained with both approaches, better results were obtained with 
data generated with the USP basket apparatus than data of the flow-
through cell method. In the two ways of association, significant 
linear regressions were obtained. Mathematical adjustment to 
different equations also differs and greater variability is observed 
with the use of the flow-through cell method. 
With the brief description of all these results, a great variability is 
observed with commercial formulations of metformin hydrochloride 
around the world and the need to work in a common dissolution test 
to verify the quality of the drug products. Apparently, no more than 
85% of drug dissolved will be achieved with a flow-through cell 
method so it would be necessary to test the hydrodynamics of 
vessels apparatuses, either basket or paddle. Our work supports 
better results with the USP basket apparatus instead of the flow-
through cell method. It is possible that the flow-through cell method 
may not be a suitable option to work with metformin hydrochloride 
tablets. This result is opposite to that reported with class II drugs 
(low solubility/high permeability) where the flow-through cell 
method had a greater discriminatory capacity than the vessels 
apparatus [28, 32]. On the other hand, health regulatory agencies of 
each country must verify, for class III drugs, a very rapid in vitro 
dissolution rate for test and reference products as well as no change 
in excipients that might affect bioavailability. Block et al., [33] have 
demonstrated that the amount and type of excipients used in 
metformin drug products can modify their dissolution performance. 
CONCLUSION 
This in vitro release study of metformin hydrochloride tablets had 
the aim of evaluating the dissolution performance of commercially 
available brands sold in the local market. Influence of the 
hydrodynamic environment of the flow-through cell method was 
tested on reference and generic drug products. Results were 
compared with data obtained using the official dissolution test and 
better results were found with the USP basket apparatus. No 
formulation evaluated achieved more than 85% of drug dissolved at 
15 min so a biowaiver cannot be suggested. Considering f2 values, 
two generic formulations showed similar dissolution profiles to 
reference but using other comparison methods all generic 
formulations were different. To demonstrate safe interchangeability 
between metformin hydrochloride generic formulations and 
reference bioequivalence studies should be performed. It is 
important post-marketing monitoring of the commercial 
formulations because health regulatory agencies of each country 
must ensure drug products with quality, safety, and efficacy at the 
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